纳络酮治疗急性酒精中毒24例

３６例急性酒精中毒病人．随机分成治疗组和对照组,分别为２４、１２例。对照组按常规治疗,治疗组在常规治疗的基础上加用纳络酮静注或静滴,结果治疗组病人苏醒和出院时间均比对照组提前。经统计学处理,两组苏醒时间差异具有非常显著性（Ｐ＜０．００１）,出院时间差异具有显著性（Ｐ＜０．０５）,提示纳络酮明显优于常规治疗。因此作者建议对急性重度酒精中毒病人应常规应用纳络酮。文中对纳络酮的作用机理进行了讨论。     

丁苯酞氯化钠注射液联合神经节苷脂治疗急性脑梗死的临床效果观察

目的:探讨丁苯酞和神经节苷酯治疗急性脑梗死的临床效果,为临床治疗提供可借鉴的方法。方法:选取2011年8月-2013年5月在我院接受治疗的94例急性脑梗死患者,随机分为治疗组和对照组,每组47例。对照组患者采取抗血小板制剂及活血药物进行常规治疗,治疗组患者在此基础上给予丁苯酞氯化钠注射液联合单唾液酸神经节甘酯进行治疗。采用NlHSS评定各组患者神经功能缺损程度,应用改良Rankin量表评定残障水平,并对两组患者的治疗效果进行对比分析。结果:两组患者治疗前的NIHSS与mRs评分无明显差异(P0.05)。两组患者治疗后的NIHSS及mRs评分较治疗前均获得改善,治疗组患者改善更为明显,治疗效果明显优于对照组,差异具有统计学意义(P0.05)。对照组患者治疗的总有效率为93.61%;治疗组患者治疗的总有效率为97.87%。治疗组的治疗总有效率明显高于对照组,差异具有统计学意义(P0.05)。结论:丁苯酞联合神经节苷酯治疗急性脑梗死具有明显的治疗效果,患者治疗后的NIHSS及mRs评分得到改善,值得临床推广采用。     

东菱迪芙治疗急性脑梗死的效果观察

目的探讨东菱迪芙治疗急性脑梗死的临床疗效及安全性。方法随机将收治的80例急性脑梗死患者分为治疗组40例,对照组40例。两组均给予抗血小板聚集、钙拮抗剂等基础治疗,并将血塞通0．25g加入生理盐水或5％葡萄糖液250ml中静脉点滴,连用14天。在此基础上,治疗组于治疗第1、3、5日给予东菱迪芙10u、5u、5u加入生理盐水250ml中静滴,每次滴注时间不少于1h。观察两组疗效、治疗前后神经功能缺损评分及治疗前后血浆FIB水平。结果治疗组显效率（75．00％）明显优于对照组（47．50％）,χ2=6．37,P〈0．05;神经功能缺损评分明显低于对照组（P〈0．05或0．01）;治疗组FIB由治疗前（3.98±0．86）g／L降至（1．84±0．42）g／L,治疗前后比较有显著性差异（P〈0．01）。结论东菱迪芙通过降低血浆FIB,增强纤溶活性,降低血粘度,改善脑循环等综合作用,对治疗急性脑梗死疗效显著、安全性好,值得推广应用。     

针灸疏经调脏法在促进脑梗死偏瘫患者康复中的价值分析

目的观察针灸疏经调脏法在脑梗死偏瘫患者康复中的应用价值。方法将我院收治的86例脑梗死偏瘫患者随机分为观察组和对照组各43例,对照组实施西医常规康复治疗,观察组采用中西医联合疗法(即在西医常规康复治疗的基础上联合应用针灸疏经调脏法),比较两组康复治疗效果、残障率及上下肢运动功能恢复情况。结果观察组患者上下肢运动功能评分均高于治疗前(均P0.05),而且治疗后评分均高于对照组(均P0.05);观察组康复治疗效果与对照组等级比较存在显著性差异(P0.05),治疗总有效率为74.42%高于对照组的53.49%(P0.05);残障率比较,观察组为62.79%明显低于对照组的88.37%(P0.05)。结论针灸疏经调脏法用于脑梗死偏瘫患者康复治疗中,能有效改善患侧上下肢运动功能,提高康复治疗效果。     

蕲蛇酶治疗急性脑梗死50例临床观察

目的 观察莘蛇酶治疗急性脑梗死的临床效果。方法 将９５例急性脑梗死患者随机分治疗组和对照组。治疗组５０例,予蕲蛇酶０．７５ｕ加入生理盐水２５０ｍｌ中静脉滴注,每日１次,７天１疗程,停药５天后进行第２疗程。对照组４５例,予低分子右旋糖酐５００ｍｌ加川芎嗪０．１ｇ静脉滴注,每日１次,７天１疗程,停药５天后进行第２疗程,两组均常规应用２０％甘露醇和尼莫地平等。２个疗程结束后进行疗效评估。结果 治疗组基本     

扶正活血祛瘀法治疗慢性足底溃疡的临床疗效观察

目的观察扶正活血祛瘀法治疗慢性足底溃疡的临床疗效。方法采用四妙勇安汤加减内服,红萝卜加马齿苋煎液浸泡外洗溃疡处,外敷呋喃西林纱布保护伤口的综合治疗方法。结果36例中治愈27例,占75．0％;好转6例,占16．7％;无效3例,占8．3％．姑论以扶正活血祛痰法内服为主,结合红萝卜加马齿苋煎液浸泡外洗与呋喃西林纱布外敷治疗慢性足底溃疡有较好的临床疗效．     

蕲蛇酶治疗急性脑梗死临床疗效观察

目的：观察蕲蛇酶治疗急性脑梗死的临床疗效和安全性。方法：治疗组100例,用蕲蛇酶治疗,对照组50例,用常规药物治疗,观察两组临床疗效及副作用。结果：蕲蛇酶治疗组治疗14天后疗效明显优于对照组,蕲蛇酶组纤维蛋白原明显下降,有2例有出血现象,结论：蕲蛇酶是治疗急性脑梗死疗效确切,安全性高的蛇毒酶药物。     

49例肾脏疾病的生化免疫检查诊断治疗临床探究

目的探讨生化免疫检查在肾脏疾病的临床治疗价值。方法选取2014年7月~2015年6月我院收治的肾脏疾病患者49例,采用随机数字表法分为观察组(n=25)和对照组(n=24)。对照组给予单纯免疫学检查,观察组给予免疫学检查联合生化检查,比较两组患者的诊断符合率及治疗效果。结果观察组患者诊疗符合率为96.0%(24/25),明显高于对照组患者的58.3%(14/24),组间比较差异具有统计学意义(χ2=9.979,P0.05);而且观察组患者诊疗满意度为92.0%(23/25),明显高于对照组的66.7%(16/24),组间比较差异具有统计学意义(χ2=4.838,P0.05)。结论生化检查联合免疫检查可有效提高肾脏疾病诊断符合率,从而提高临床疗效,值得推广。     

依达拉奉联合法舒地尔应用于急性脑梗死患者的治疗效果观察

目的:观察依达拉奉联合法舒地尔应用于急性脑梗死(acute cerebral infarction,ACI)患者的治疗效果及其安全性。方法:选取我院2011年1月-2014年1月收治的急性脑梗死患者96例,随机分为观察组和对照组,每组48例。观察组患者应用盐酸法舒地尔联合依达拉奉静脉滴注,对照组患者单独应用盐酸法舒地尔静脉滴注射。观察并比较两组患者的治疗效果、神经功能缺损的变化情况及不良反应的发生情况等。结果:治疗前,两组患者NIHSS、BI评分及NSE水平比较无明显差异(P0.05);治疗后,两组患者NIHSS、BI评分及NSE水平均较治疗前明显改善,且观察组改善更明显,差异具有统计学意义(P0.05);观察组治疗总有效率高于对照组,差异具有统计学意义(P0.05);两组不良反应发生率无明显差异(P0.05)。结论:依达拉奉联合法舒地尔对急性脑梗死患者的临床效果显著,不仅可以改善患者的神经功能缺损情况,而且能够改善NSE水平,值得临床推广应用。     

依达拉奉联合血栓通治疗急性脑梗死的临床疗效观察

目的观察依达拉奉联合血栓通治疗急性脑梗死的临床疗效及临床应用价值。方法选取2013年9月~2014年12月我院收治的47例急性脑梗死患者为研究对象,随机分为对照组23例,治疗组24例。对照组采用血栓通进行常规治疗,治疗组采用依达拉奉联合血栓通治疗,并对两组的治疗效果进行比较分析。结果治疗组显效20例,显效率为83.3%;对照组显效16例,显效率为69.6%。两组患者比较差异具有统计学意义(P0.05)。结论依达拉奉联合血栓通治疗急性脑梗死患者的效果明显,且安全,值得临床推广应用。     

Recent advances in the study of Kaposi's sarcoma-associated herpesvirus replication and pathogenesis

It has now been over twenty years since a novel herpesviral genome was identified in Kaposi's sarcoma biopsies. Since then, the cumulative research effort by molecular biologists, virologists, clinicians, and epidemiologists alike has led to the extensive characterization of this tumor virus, Kaposi's sarcoma-associated herpesvirus(KSHV; also known as human herpesvirus 8(HHV-8)), and its associated diseases. Here we review the current knowledge of KSHV biology and pathogenesis, with a particular emphasis on new and exciting advances in the field of epigenetics. We also discuss the development and practicality of various cell culture and animal model systems to study KSHV replication and pathogenesis.     

The structure, reproduction and taxonomy of Vidalia and Osmundaria (Rhodophyta, Rhodomelaceae)

Comprises species occurring mostly in subtidal habitats in tropical, subtropical and warm-temperate areas of the world. An analysis of the type species, V. spiralis (Sonder) Lamouroux ex J. Agardh, a species from Australia, establishes basic characters for distinguishing species in the genus. These characters are (1) branching patterns of thalli, (2) flat blades that may be spiralled on their axis, (3) width of the blade, (4) primary or secondary derivation of sterile and fertile branchlets and (5) position of sterile and fertile branchlets on the thalli. Application of the latter two characters provides an important basic method for separation of species into three major groups. Osmundaria , a genus known only in southern Australia, was studied in relation to Vidalia , and its separation from the Vidalia assemblage is not accepted. Species of Vidalia therefore are transferred to the older genus name, Osmundaria. Two new species, Osmundaria papenfussii and Osmundaria oliveae are described from Natal. Confusion in the usage of the epithet, Vidalia fimbriala Brown ex Turner has been clarified, and Vidalia gregaria Falkenberg, described as an epiphyte on Osmundaria pro/ifera Lamouroux, is revealed to be young branches of the host, Osmundaria prolifera.     

New or rare chromosome counts in Artemisia L. (Asteraceae, Anthemideae) and related genera from Kazakhstan

Fifteen chromosome counts of six Artemisia taxa and one species of each of the genera Brachanthemum, Hippolytia, Kaschgaria, Lepidolopsis and Turaniphytum are reported from Kazakhstan. Three of them are new reports, two are not consistent with previous counts and the remainder are confirmations of very scarce (one to four) earlier records. All the populations studied have the same basic chromosome number, x = 9, with ploidy levels ranging from 2x to 6x. Some correlations between ploidy level, morphological characters and distribution are noted.     

肝癌中HBV和HCV基因和抗原的分布及意义

采用原位分子杂交方法检测HCV RNA及HBV X基因;采用免疫组织化学方法研究HCV核心抗原,非结构区C33c抗原及HBxAg在肝细胞肝癌中的定位及分布.结果表明(1)HCV RNA、HBV X基因在肝细胞肝癌组织检出率分别为40%(55/136)和82%(112/136).HCV RNA定位于癌细胞的胞浆内,阳性细胞呈散在、灶状及弥漫分布三种形式;HBV X基因在肝癌细胞中的分布呈胞浆型、核型及核浆型,阳性细胞也呈上述三种分布形式;(2)HCV C33c抗原、核心抗原在肝细胞肝癌中的阳性率为81%(133/164)及86%(141/164).C33c抗原定位于癌细胞及肝细胞的胞浆内;核心抗原既定位于癌细胞核中,又可定位于胞浆中.C33c抗原阳性细胞以灶状分布为主;而核心抗原阳性细     

Selection with two alleles and complete dominance

For a plant selection model with frequency-independent viabilities, fertilities and selfing rates, it is shown that apart from global fixation, for certain parameter combinations a protected polymorphism and facultative fixation (either allele may become fixed according to initial frequencies) may both occur. Facultative fixation requires different selling rates for the dominant and recessive type. Protection of the polymorphism requires resource allocation for male and female function. In this connection the problem of purely genetically caused population extinction is discussed.
For general frequency dependence and regular segregation, the chances for establishment of a completely recessive gene are compared to those of a completely dominant gene. It is proven that the process of establishment of the recessive gene, despite a fitness advantage, may be considerably endangered by drift effects if random mating prevails. The recessive gene may reach the same effectivity in establishment as a dominant gene, only if the recessive homozygote mates exclusively with its own type during the period of establishment.